Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00975767 · ClinicalTrials.gov registry record · Phase 1
A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Mirati Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 126
- Enrollment target
NCT00975767: Clinical Trial Phase 1 study, sponsored by Mirati Therapeutics.
NCT00975767 is a Phase 1 study that was terminated before completion, run by Mirati Therapeutics. The registered enrollment target is 126 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (110% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00975767, a Phase 1 study, was terminated before completion, sponsored by Mirati Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 126 participants
- Enrollment target
Study Summary
The main purpose of this study is to assess the safety profile of MGCD265 when administered in combination with the marketed anticancer drugs erlotinib and docetaxel.
Interventions
- DRUG MGCD265+erlotinib
- DRUG MGCD265+docetaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2009-08 |
| Est. Completion | 2014-08 |
| Phase | Phase 1 |
Why NCT00975767 stopped before completion
NCT00975767 is an interventional study that assigns participants to a tested intervention. The registered 126 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (110% higher).
The record links to 0 conditions, and to 2 interventions - of which MGCD265+erlotinib is the first listed.
NCT00975767 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00975767 about?
NCT00975767 is a clinical study titled "A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer". The main purpose of this study is to assess the safety profile of MGCD265 when administered in combination with the marketed anticancer drugs erlotinib and docetaxel.
What is the current status of trial NCT00975767?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 126 participants. The study started on 2009-08. Estimated completion is 2014-08.
What interventions are being tested in trial NCT00975767?
The interventions under investigation include: MGCD265+erlotinib (DRUG), MGCD265+docetaxel (DRUG).
Who is sponsoring clinical trial NCT00975767?
This trial is sponsored by Mirati Therapeutics, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00975767's enrollment target sits among peer trials
126 461st of 2000 higher than 1,534 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01873131 · 126 participants · NA
A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn
- NCT02621645 · 126 participants · Phase 4
TRAP Intervention STudy: Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence
- NCT03838107 · 126 participants
Markers of Trajectory in Pediatric CRPS
- NCT03906422 · 126 participants · NA
Comparison of Patient-reported Pain After Initial Archwire Placement
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia